Many South Asian people probably need pre-diabetes care

Citation for published version:
Bhopal, R & Fischbacher, CM 2002, 'Many South Asian people probably need pre-diabetes care' BMJ, vol. 325, no. 7370, pp. 965. DOI: 10.1136/bmj.325.7370.965/a

Digital Object Identifier (DOI):
10.1136/bmj.325.7370.965/a

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
BMJ

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Prevention and cure of type 2 diabetes

General practitioners are treating more cases of diabetes

Editor—Most studies measuring the prevalence of diabetes have been carried out in one locality and have generally measured point prevalences. Hence, although the prevalence of diabetes in England and Wales is increasing,1 time trend data on prevalence and future projections based on sound data are both lacking. We recently estimated the prevalence of diabetes in England and Wales between 1994 and 1998 using data from 210 general practices with a combined list size of 1.2 million.2

We found that the overall prevalence of diabetes during this period increased from 1.90% to 2.43% in males and from 1.60% to 2.04% in females. This striking increase in the prevalence of diabetes in primary care is likely to be due to a combination of factors, including better case ascertainment, rising rates of obesity, an ageing population, and an increase in both the size and average age of the ethnic minority population. Overall, 29%, 48%, and 24% of males with diabetes and 26%, 48%, and 26% of females with diabetes were treated by diet, oral hypoglycaemic drugs alone, and insulin respectively.

We estimated around 1.15 million people had a diagnosis of diabetes mellitus in England and Wales in 1998. If the age-specific prevalence of diabetes increases by a modest 30% over the next 25 years (less than predicted by many authorities), then the number of people with diabetes will increase by 70%, to 1.96 million by 2023. If age-specific prevalence increases by more than 30%, then the increase in the number of cases will be even larger.

Our findings illustrate the potential size of the diabetes epidemic facing England and Wales. The epidemic will have major implications for the NHS, which will have to provide diabetic services for these patients, as well as deal with the clinical and psychosocial complications resulting from diabetes. We therefore reinforce the need to tackle the underlying causes of this epidemic, particularly by increasing levels of physical activity and reducing rates of obesity in our society.3

Azeem Majeed professor of primary care University College London, London WC1H 9QU a.majeed@ucl.ac.uk

Angela Newnham senior lecturer in public health medicine Thames Cancer Registry, King’s College, London SE1 3QD

Ronan Ryan research officer Office for National Statistics, London SW1V 2QQ

Kamlesh Khunti senior lecturer in general practice Department of General Practice, University of Leicester, Leicester LE5 4PW


3 Dr Curran and Partners. Staying healthy. How to stay healthy. Available at: www.claphamhealth.org.uk/Health/Plan (accessed 16 October 2002.).

Let’s move upstream to obesogenic environments, please

Editor—Another BMJ brings yet another editorial on obesity and associated diabetes.1 Once again there is no reference to the real cause of this problem—obesogenic environments.

Why is it that commentators constantly shy away from digging deeper? Why do they repeatedly refuse to venture upstream? It must be blindingly obvious to everyone by now that there is, and never will be, any conventional medical treatment for obesity or diabetes. Doctors should come clean and tell patients and populations that the cure lies not with medicine but in how our societies are created.

Children are denied vital play space because politicians favour selling play space to developers. Sixty per cent of the green space used for housing in London in the past 10 years came from the sale of playing fields (Open spaces conference, Bankside Trust, London, March 2002). We exclude children’s play from our streets by permitting a 30 mph urban speed limit. If we are to encourage an extra 3 miles of walking daily to enable 4 kg weight loss, reducing the risk of developing diabetes by 58%, then we must create an environment where people are able to walk. It is facile and cruel just to tell people that they must walk more. Healthy people need healthy environments.

Politicians have the central role in creating healthy populations. They should stop pandering to powerful lobbies such as the pharmaceutical, motorizing, food, and tobacco industries. If we as doctors do not tell them that they have the prime responsibility for health then we will continue to abuse us by heaping us with impossible responsibilities for changing the health of our nation. When we inevitably fail then they will give us the blame.

General practice in the United Kingdom is currently tittering on the brink of such stupidity in the shape of a new medical contract that will enslave us into performing the impossible tasks of reducing blood pressure/weight/glycated haemoglobin concentrations/cholesterol concentrations, etc. We will soon be shackled to tick box medical consultations stuffing irrelevant data into computers in a pointless and ever increasing spiral of ineffectual intervention while the good that we can do, but which has never been recognised or rewarded, will simply wither and die.

Perhaps the next obesity and diabetes editorial should be commissioned from a sociologist?

Colin Guthrie general practitioner

14/48 Dumbarton Road, Glasgow G14 9DW
grey_triker@hotmail.com


Many South Asian people probably need pre-diabetes care

Editor—in their editorial Venkat Narayanan et al make a case for the American Diabetes Association’s recommendation to screen for pre-diabetes in people over 45.1 Pre-diabetes is defined as either impaired glucose tolerance (two hour glucose concentration 7.8-11 mmol/l after a glucose load) or an impaired fasting glucose concentration of 6.1-6.9 mmol/l. Those screening positive are at high risk of cardiovascular diseases and diabetes and therefore would be counselled on weight loss and increasing physical activity.

This recommendation has profound implications for the health care of South Asian populations originating in the Indian sub-continent and for whom the prevalence of diabetes is reaching epidemic levels.2

Azeem Majeed


subcontinent living in urban settings where pre-diabetes is common.\(^3\)

We reported a secondary analysis of the Newcastle heart project based on age and sex adjustment using the standard population of England and Wales on the prevalence of diabetes and pre-diabetes in those aged 25-74 of South Asian (n=680), Chinese (n=370), and white European origin (n=824). Weighted percentages and unweighted numbers for South Asians show that the prevalence of impaired fasting glucose (138/680) and impaired glucose tolerance (140/680) was 19%. The prevalence of pre-diabetes on either definition was 30.5% (226/680). The prevalence of diabetes based on two hour glucose measures was 20.1% (160/680); on the American criteria, 21.4% (226/680). The prevalence of pre-diabetes on either definition was 30.5% (140/680) was 19%.

Only 49% (295/680) of the population had normal glucose tolerance. A programme of care for pre-diabetes would be needed for about half of the South Asian population in the 25-74 age group, a formidable task about half of the South Asian population in the 25-74 age group, a formidable task complicated by issues discussed below.

Narayan et al would prioritise screening in those with a body mass index of 25 or more, a marker of excess adipose tissue. Markers of obesity, including body mass index, do not have equivalence across ethnic groups.\(^3\) South Asians in the United Kingdom have slightly lower indices but higher waisthip ratios and greater skinfold thicknesses. Body mass index is not a good indicator of adiposity in South Asians, and a lower cut-off point for being overweight is necessary.

If interventions are to work people need to perceive risk and benefits accurately. In the Newcastle heart project, South Asian women’s perceptions of their own weight did not match guidelines on being overweight and obese.\(^4\) A substantial proportion of overweight South Asian women perceived themselves to be of normal weight, but women of European origin had the opposite problem. South Asians’ knowledge of the causation and prevention of diabetes and heart disease in nearby South Tyneside was poor.

Finally, lack of physical exercise poses a huge challenge (reference available at bmj.com/cgi/eletters/325/7361/1035#25585). Although the task of halting the process of pre-diabetes becoming diabetes is urgent, careful evaluation of screening and interventions is essential.

R Bhopal
Bruce and John Usher professor of public health
C M Fischbacher
clinical research fellow
Division of Community Health Sciences (Public Health Sciences), University of Edinburgh, Edinburgh EH1 9AG

We thank Dr Nigel Unwin for helpful advice in preparing this letter.

---


---

**Women with gestational diabetes should be targeted to reduce cardiovascular risk**

**Editor—Sattar and Greer discuss the probability that complications in pregnancy may predispose women to vascular and metabolic disease in later life.** The link between pregnancy complications and coronary heart disease remains unexplained. We believe that during pregnancy the hormonal and other stresses provoke cardiovascular and metabolic abnormalities in susceptible individuals, which may recur and become permanent as the patient ages. Many of these are coronary risk factors; disturbances in glucose metabolism, which underlie the development of gestational diabetes, are a good example.

An uncomplicated pregnancy is characterised by obvious changes in lipid metabolism early in pregnancy.\(^3\) These include the formation of small, dense subfractions of low density lipoprotein, an important risk factor for atherosclerosis.\(^4\) These are retained in the arterial intima, are more easily oxidised, and once oxidised are rapidly taken up into macrophages, creating foam cells and atherosclerotic plaques. The additional effect of pregnancy on lipid metabolism in people with diabetes and those at increased risk of developing diabetes may markedly increase cardiovascular risk in these women.

We recently studied three groups of pregnant women: healthy controls (n=17, mean age 29.2 (SD 1.1 years)), women with type 2 diabetes (n=12, mean age 32.5 (1.6) years), and women with gestational diabetes mellitus (n=12, mean age 32.8 (1.5) years). Venous blood was taken during each trimester (first, 1-13 weeks; second, 14-27 weeks; and third, 28 weeks to term). Samples were analysed for subfractions of low density lipoprotein (polycrylamide gel electrophoresis) and triglycerides. A score for low density lipoprotein was calculated from the area under the curve for each subfraction; the higher the score the smaller, denser and more atherogenic the low density lipoprotein particles.\(^4\)

Triglyceride concentrations increased throughout pregnancy in all groups. This was most obvious during the second trimester in women with gestational diabetes (figure). Low density lipoprotein score progressively increased throughout pregnancy, implying the formation of potentially atherogenic lipoproteins. These changes were exaggerated in women with type 2 diabetes but more particularly in those with gestational diabetes (figure).

We found that pregnancy and diabetes have an additive effect on the development of an atherogenic lipid profile. Importantly, this is exaggerated earlier in pregnancy in gestational diabetes. This finding may identify women who are particularly susceptible to the premature development of atherosclerosis. We agree with Sattar and Greer that women with gestational diabetes should be targeted during and after pregnancy with advice on diet and lifestyle to try to modify this excess cardiovascular risk.

V Toescu
research associate
v.toescu@bham.ac.uk

S L Nuttall
postdoctoral fellow
M J Kendall
professor of clinical pharmacology
U Martin
senior lecturer in pharmacology
F Dunne
senior lecturer in medicine

Division of Medical Sciences, Queen Elizabeth Hospital, Birmingham B15 2TH

---


---

The global response to mental illness

First line care facilities and support for providers have to be improved

Editor—Thornicroft and Maingay highlight the inadequacy of international responses to mental illness.1 In low income countries the burden of mental illness is amplified by financial insecurity, poverty, and partition of families, if not by violence and war. Prevention in mental health is intimately linked with overall human development. Individual care is also necessary. In some societies religious or traditional healers still provide culturally relevant and socially acceptable responses to problems labelled as mental illness. Nevertheless, mental suffering is manifest among users of modern medical services, where it goes largely unrecognised.

Besides poor availability of drugs, human resources are of utmost importance in understanding the apparent neglect of mental health problems. Doctors and nurses in low income countries are often described as rude to their patients,2 partly because they have low salaries and poor professional perspectives, which affects their morale, self confidence, and dedication.3 Some have problems similar to those of their patients—for example, domestic violence or living with HIV. Some are not prepared to face the emotional burden of listening to patients’ suffering. Adequate professional support is unusual, and dealing with emotions is seldom valued by the organisational culture.4

If health care in low income countries is to be oriented towards more biopsychosocial approaches, efforts have to include improving first line care facilities and support for providers. Well functioning first line facilities are crucial to integrate mental health programmes accessible to the population. This does not rule out specialised services, but these tend to remain concentrated in cities and are often of limited accessibility financially. In the case of mental health services, stigmatisation furthermore limits their acceptability to potential users.

The integration of mental health programmes in first line care facilities should of course not be detrimental to the comprehensive character of the service delivered. The purpose is not to divert available resources to serve a specific programme but to take advantage of the existing relations between a service and a community to widen the scope of responses provided locally. Health care in low income countries is increasingly thought of as a series of vertical programmes, so the need for access to regular health care is crucial, and specific programmes must strengthen general services rather than weaken them. Indeed, mental health programmes may improve first line care. Concerns for mental health are likely to promote listening skills, to foster patient centred care, and to broaden the professional identities of care providers, currently focused on biomedical issues. This could be an important step on the way to quality general practice adapted to social and cultural contexts.5

Monique Van Dormael

Institute of Tropical Medicine, Public Health Department, Nationalalelaan 155, 3000 Antwerp, Belgium

Jean-Pierre Unger

senior lecturer

Institute of Tropical Medicine, Public Health Department, Nationalalelaan 155, 3000 Antwerp, Belgium

Focus on mental health means new opportunities for developing countries


Discontinuation of thioridazine

R Srinivasa Murthy

programme director

Nimhans, Box 2900, Bangalore 560029, India

murthy@nimhans.kar.nic.in

Discontinuation of thioridazine

Risk must be balanced

Editor—Until the Committee on the Safety of Medicines restricted the use of thioridazine in 2000, it was the most widely used antipsychotic drug in the United Kingdom, with 30 million prescriptions in 2000.1 Discontinuation meant that patients with severe mental illness suddenly had no access to a useful drug.

This article summarises the effects of discontinuing thioridazine from the point of view of those who care for people who have been prescribed it and those who care for patients who have suddenly had their treatment stopped. People who actually underwent the withdrawal process are interviewed, together with their doctors and nurses, to explore what happened to them, and what the effects of discontinuing thioridazine were.

Thioridazine is a butyrophenone—like antipsychotic with sedative effects that were used (and still are) by many people to help them sleep. However, in the long term it has several problems.

1. It is associated with increased risk of cardiac death. The rates of cardiac death are greater in patients receiving thioridazine than in those receiving another antipsychotic drug.2

2. It is associated with increased risk of cardiac death. The rates of cardiac death are greater in patients receiving thioridazine than in those receiving another antipsychotic drug.2

3. It is associated with increased risk of cardiac death. The rates of cardiac death are greater in patients receiving thioridazine than in those receiving another antipsychotic drug.2

4. It is associated with increased risk of cardiac death. The rates of cardiac death are greater in patients receiving thioridazine than in those receiving another antipsychotic drug.2

5. It is associated with increased risk of cardiac death. The rates of cardiac death are greater in patients receiving thioridazine than in those receiving another antipsychotic drug.2

The heart of the new article is a letter from Professor Chris Goodwin, the consultant psychiatrist with the most experience of withdrawal in the United Kingdom, which describes the efforts made to reduce the risk of cardiac death and the success achieved.

The article also reports a case study of the withdrawal of thioridazine from a 45-year-old woman in the United Kingdom. The following letter from the patient describes how her mental illness was treated with thioridazine, and her experience of the withdrawal process.

The patient was 45 and had had schizophrenia for 20 years. She had been prescribed thioridazine for about 15 years. She had heard voices and ideas and had been hallucinating for many years. She had been treated with thioridazine for at least 10 years. She had been prescribed other antipsychotic drugs but had never taken them because they made her feel sick. She had been prescribed thioridazine by several doctors but had never complained about the doctor’s or the nurse’s care. She had never seen a social worker or a mental health nurse. She had never had a job or a regular routine. She had been living in a supported living arrangement for several years.

The patient’s treatment had been stopped and she was now taking no medication. She was now feeling well and had no difficulty in thinking. She was now able to do her shopping and to prepare her own meals. She was now able to walk for short distances and to go out with her friends. She was now able to take part in group activities.

The patient was now able to think clearly and to plan her day. She was now able to take part in group activities. She was now able to do her shopping and to prepare her own meals. She was now able to walk for short distances and to go out with her friends. She was now able to take part in group activities.

The patient was now able to think clearly and to plan her day. She was now able to take part in group activities. She was now able to do her shopping and to prepare her own meals. She was now able to walk for short distances and to go out with her friends. She was now able to take part in group activities.
seems that thioridazine is much safer than other effective drugs such as aspirin, which continues to be sold over the counter. Even if adverse events are under-reported, there is far more practical evidence of long term safety for thioridazine compared with much more expensive and much less tried and tested drugs. A recent study noted that many new drugs have a high rate of serious side effects which go undetected until late in postmarketing surveillance. The Committee for the Safety of Medicines needs to balance these relative risks.

The manufacturers of thioridazine have raised few objections to the restricted use of thioridazine because it is an extremely cheap drug, costing only a few pence compared with newer antipsychotics that may be up to a hundred times more expensive, as well as having different and sometimes distressing side effects. The prescription costs of antipsychotic drugs has risen sharply in Scotland in the past two years.

Anecdotally, considerable numbers of patients with hypomania, anxiety, and agitation are having considerable problems in adjusting to a change of drugs, and, as Davies et al point out, informed consent may be a problem. 1 It would be very helpful if the National Institute for Clinical Excellence or Health Technology Board for Scotland reviewed the evidence, risks, and benefits of thioridazine, and considered more humane guidelines for its future use. It seems quite wrong to deprive so many patients of a well tried drug.

Ann F Bisset medical adviser
Public Health Medicine, Information and Statistics Division, Edinburgh EH2 2SJ
ann.bisset@virgin.net

Competing interests: None declared.


What happened to thioridazine?

Editor—The article by Davies raised some important issues on discontinuation of thioridazine in populations with learning disability. 2 We had successful withdrawal of thioridazine in our services in Salford district.

We looked at the following issues before withdrawal of thioridazine:

(1) Initial diagnosis before thioridazine was prescribed
(2) Duration and dose of treatment
(3) Review of previous psychiatric treatment including attempts to reduce or stop thioridazine.

Results indicated that 28 out of 175 patients under the care of a psychiatrist specialists in learning disability received thioridazine. Twenty three patients received small doses (50-100 mg) for many years. The main indication for use was marked challenging behaviour (12 patients). Based on the above information, a decision was made to gradually reduce (12 patients) or suddenly stop thioridazine (16 patients).

As an alternative, a tranquiliser was prescribed for all 28 patients. Risperidone was the most commonly used atypical antipsychotic drug because of some evidence of its effectiveness in challenging behaviour. 3 A review of patients’ mental state three months after the substitution of tranquillisers indicated that twenty one patients either remained stable or improved, and seven patients deteriorated. These seven patients subsequently improved, either by a change to a different psychotropic drug or by adjusting the dose of existing drugs. No patient needed to restart taking thioridazine.

Review of previous psychiatric treatment helped us to identify instances of rebound increase in behavioural problems when thioridazine was stopped. It also prompted us to avoid using neuroleptics that were either ineffective or caused unacceptable side effects. Evidence of rebound aggression on stopping neuroleptics was also observed by Mos et al. 4 This led us to withdraw thioridazine gradually in most cases.

In our opinion risk associated with the withdrawal of thioridazine was managed carefully and minimised by taking into account the diagnosis, the dose and duration, and consequences of previous reduction in medication followed by a careful strategy of either gradual reduction or sudden stoppage with replacement of alternative tranquilisers in appropriate doses.

Pernia Arshad consultant in learning disability psychiatry
srirdhar777@yahoo.co.uk
Mary Morcos senior house officer in psychiatry
Baskaran Sridharan specialist registrar in psychiatry
Department of Psychological Medicine, Meadowbrook Unit, Salford M6 8HG

Competing interests: None declared.


Temple healing

Healing temples may breed superstitions

Editor—Raguram et al report that when patients with psychiatric disorders stay briefly at a healing temple most of them improve significantly. 5 They describe at length the legend of Muthuswamy and endorse the local notion that the temple is endowed with mysterious healing power.

This suggestion could leave unwary patients with an unjustifiably favourable impression that healing temples can cure their diseases. Most Indians are deeply religious and superstitious. In Indian villages, myths, misconceptions, blind beliefs, and superstitions abound. Quacks and local healers thrive on the illiteracy and ignorance of naïve and gullible people and try to hoodwink them into believing that they have magic cures for their ills.

Muthuswamy temple might be an exception, for it does not charge people who stay there, and, more importantly, offers no specific healing rituals. But local newspapers and quacks may distort the conclusions of the study by pointing out that even a Western journal recognises—and endorses—the hidden healing powers of Indian temples. The news might make thousands of people seek a cure for their chronic diseases in temples and shrines. Even people with potentially curable diseases may choose not to see doctors in the hospitals but seek shelter in holy places. The consequences of such an attitude could be terrible.

History tells us that when tuberculosis was a formidable foe in the 19th century people thought that their best chance of conquering the disease was residing in a sanatorium. 6 Patients and their doctors all over the world believed that a salubrious environment, clear mountain air, and nutritious food was the best way to ensure cure. Thousands of patients with tuberculosis chose Switzerland as their health destination. Myths were woven around sanatoriums, and people who could afford it resided in what they considered “magic mountains” for as long as 10 years.

The sanatorium made most patients feel better for a while, but their infection progressed unabated and killed all of them. Doctors and lay people took 75 years to realise that sanatorium was a highly expensive—and terribly ineffective—intervention for getting rid of tuberculosis.

I think healing temples for alleviating psychiatric disorders and magic mountains for curing tuberculosis share one thing: a strong placebo effect fostered by local superstitions and traditions. Patients with chronic and psychiatric diseases often do not go to their doctors, but we should avoid creating an impression among the public at large that healing temples are capable of restoring their health.

S P Kalantri professor of medicine
Mahatma Gandhi Institute of Medical Sciences,
Sevagram 442102, India
sp_kalantri@rediffmail.com

Muthuswamy temple
Spiritual care is important

Editor—As a senior house officer in an acute psychiatric ward in central London, I can understand why there was improvement in the condition of the psychiatric patients who resided in the Muthusamy temple in India, as reported by Raguram et al. Patients were brought into a place of ‘refuge’ with people similar to them, who understood their condition. This would result in less expressed emotion and distress and better care of the individual, not only by relatives but also by temple staff in a supportive, non-threatening environment. Here people can make sense of their mental illness. This is good “psychosocial” psychiatric care.

How does this contrast with an acute psychiatric ward? Patients are placed in a busy and emotionally charged environment with others who may be more disturbed, usually with little support from relatives. Relatives’ visiting rights are limited, and patients may not have anyone to confide in. Here there is good “biological” psychiatric care.

What is the way forward? We need a more holistic approach to inpatient psychiatric care to try to “heal” our patients, rather than just treat their psychopathology. Family members need to be fully involved. For serious mental illness, the individual’s spiritual needs, which are important to most people, must be looked after. The power of cultural beliefs and spirituality is important, as seen by belief in the healing power of the temple, and this is largely neglected in modern psychiatry. The result is increased stigmatisation of psychiatric wards, which are viewed more as places of containment than refuge.

What would have happened if Raguram et al distributed psychotropic drugs to the patients at the temple? I am sure their condition would improve more quickly as there would be “holistic biopsychosocial healing.” I hope for the day when psychiatric temples, or places of worship, without stigma and with a cultural belief of healing, will replace psychiatric wards. Then holistic biopsychosocial care of mental illness can truly be achieved.

Cyrus A Abbasian senior house officer
York Clinic, Guy’s Hospital, London SE1 3RR
abbasian@hotmail.com

Author’s reply to responses

Editor—Our study was motivated by previous clinical and epidemiological research on schizophrenia in Bangalore, India. Traditional sources of help, such as local healers and healing temples, figured prominently in patients’ previous help-seeking, which suggested that research was needed to examine their experiences at healing temples more closely.

We reported improvement in symptoms, and these findings were as surprising to us as to many readers of the article. But we recognised the diversity of practices used in various settings of traditional healing and emphasised that benefits documented at one site should not be generalised to all healing temples and that our findings should not be construed as professional endorsements of diverse traditional healing practices.

Nevertheless, our study does indicate the value of traditional community resources in caring for serious, chronic mental illnesses and shows the effect of a supportive environment that derives its healing power from the cultural values of the community. Inasmuch as such environmental supports may be lacking in many institutions for mental health care, we should welcome—rather than fear misuse of—such healing contexts. Moreover, pertinent social supports and cultural influences may profitably complement psychopharmacological and neurophysiological frameworks that guide effective psychiatric practice.

Larger questions about the impact of the sociocultural context of mental health care for people with chronic mental illness in India also motivated our study. Policy making and plans for community programmes should benefit from consideration of the nature of the existing local system which planned interventions may try to replace or complement. For that, research should attend to two broad aims.

Firstly, an assessment of the impact of traditional healing is needed with reference both to local and professional criteria, as reported in our article.

Secondly, the cultural epidemiology of mental health problems—with reference to their local experience, meaning, and behaviour—is also needed. Findings have been presented in a thesis by Venkateswaran (2001) and will be elaborated elsewhere.

With appreciation of growing interests in complementary approaches to health care, and recognising the importance of attention to sociocultural contexts for effective community mental health planning, scientific studies are both warranted and needed. They encourage an ongoing process of critical rethinking to ensure the relevance of psychiatric practice locally and to enhance the acceptance and effectiveness of community mental health programmes.

R Raguram professor of psychiatry
Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bangalore 560 029, India

Primary prevention strategies for cardiovascular disease

Editor—The assumptions made by Marshall and Rouse in their study are too broad and may lead to erroneous conclusions. Using the Framingham equation with average values is going to stratify the population only by age, sex, and diabetes status. Such stratification is simplistic and will prove only that older people and people with diabetes are more at risk. By assuming that the subjects are non-smokers Marshall and Rouse exclude the most important single weightings in the Framingham calculation. Most practices have a register of smoking status for most of their patients, so this should be included.

Marshall and Rouse admit that their method may not be able to screen all of the population, so some will lose out. By concentrating on the oldest patients and patients with diabetes first, it will not detect some who have most to lose, such as 50 year old smokers with hypercholesterolaemia and hypertension. Adding a few extra years to the life of a 70 year old non-smoking normotensive diabetes patient may be laudable, but just because it is easier and cheaper does not mean that these patients should be prioritised to be assessed first, as this method seems to suggest.

Many of Marshall and Rouse’s other assumptions do not fit well with the day to day realities of general practice. Few general practitioners would be able to stabilise anti-hypertensive treatment with only four prescriptions and two follow up consultations in a year. Government policy is to issue 30 days’ supply, so Marshall and Rouse underestimate dispensing costs. Not all of this work can or should be done by practice nurses. Other diagnoses will be found requiring medical intervention, and many patients need more careful clinical assessment than a simple protocol provides. Marshall and Rouse’s assumption that two 20 minute consultations by a practice nurse are all that is needed to treat is wrong, so their economic argument is flawed.

Their conclusion about statins and angiotensin converting enzyme inhibitors costing more, so strategies avoiding these may allow more disease to be prevented is odd. It would be actionable to omit a cholesterol measurement on a high risk patient or if a high level was found, negligent not to treat. Avoiding them is not an option in the real world.

This paper adds little to the subject other than confusing people into thinking there is a quick and cheap method of cutting short the hard and expensive, but necessary, work of finding all those at risk of heart disease and lengthening their lives.

Gill Tyerman general practitioner
Peter Tyerman general practitioner
Rotherham Road Surgery, Barnsley S71 1UT
Trefor J Roscoe general practice informatics tutor, North Trent
Institute of General Practice, Northern General Hospital, Sheffield S7 1AU

Risk-benefit ratio is important in treating atopic dermatitis

Enrrow—Williams acknowledges the efficacy of tacrolimus and pimecrolimus in atopic dermatitis but subsequently his editorial is negative and lacks any patient perspective. The issue lies not in clinicians’ disembodied comparisons of efficacy but in what treatment provides patients, or their affected children, with the most acceptable benefit-risk ratio. Only 40% of patients with eczema are reportedly satisfied with their treatment, and work from Williams’ own department has shown that in many cases using a topical corticosteroid produces risks, especially of skin thinning, which are unacceptable high to the patients, resulting in non-compliance and inadequate treatment.

Patients’ fears about steroids can hardly be dismissed as irrational, even though they may be exaggerated. Far from being rare, the risks of adverse events from the use of steroids are directly related to the duration, quantity, and potency of the steroid used. Thus today’s patients are just as much at risk as before unless they choose to endure the misery of their condition and leave it under-treated. The main fear which patients had was of skin thinning. Topical tacrolimus and pimecrolimus are free of this and other risks associated with steroid use and offer a realistic alternative of proved efficacy whatever their potentials relative to each other or to corticosteroids.

Although the editorial declares the use of probiotics harmless, the long term risks of using such strategies are currently unknown and the subject of debate. Their safety has not been tested on anything like the 13 000 included in the trials of tacrolimus and pimecrolimus.

As with any new treatment, close monitoring will be mandatory, but longer term studies with pimecrolimus and tacrolimus show no clinically significant increase in infections or skin cancers. Since the drugs are non-mutagenic, are absorbed only slightly, and do not permanently impair primary immune responses, an increased risk of cancer either topical or visceral is most unlikely. It is of note that with over 40 years of use of potent topical steroids—which not only deplete cutaneous Langerhans cells but are highly immunosuppressant as well as being systematically absorbed—there is no evidence that they predispose to cancer either cutaneous or systemic. These new drugs for atopic dermatitis are welcomed by patients, parents, and doctors as a wholly new treatment option for this demoralising disease. They are the first major advance in its management in half a century.

B Roger Allen consultant dermatologist Department of Dermatology, University Hospital, Queen’s Medical Centre, Nottingham NG1 1OU. brallen1@aol.com

Thomas A Luger Department of Dermatology, Westphalian Wilhelms-University of Münster, Von-Esmarch-Strasse 56, D-48149 Münster, Germany luger@uni-muenster.de

The authors have received funding from Fujisawa and Novartis to advise on and carry out clinical studies on tacrolimus and pimecrolimus.

1 Williams H. New treatments for atopic dermatitis. BMJ 2002;324:1538-4

Using evidence based tools to manage chronic illness

Enrrow—Von Korff et al discussed how to organise care for chronic illness. Since 1993 we have used evidence based care tools that combine patients’ needs, values, and perceptions with scientifically valid patient based assessments to measurably improve and maintain health related quality of life.

We routinely use the functional health assessment questionnaire (SF-36) and the Zung depression, Beck anxiety, and Epworth sleepiness scales. We integrate these data with patient self care data

Authors’ reply

Enrrow—Our principal conclusion has not been challenged: authors of guidelines should explicitly model the resource implications and health benefits of following their recommendations. The table shows the results of modelling using Tyerman et al’s suggestions: 12 prescriptions a year, all assessment and follow up by doctors, patient assessment taking 1 hour, stabilisation and follow up taking 2 hours over 5 years. A practice that prescribes 200 patients to assess prevents 82% as much cardiovascular disease at 57% of the cost.

Simvastatin costs more and is less effective than identifying and treating new patients with aspirin and antihypertensive drugs. Five years’ treatment with simvastatin 10 mg costs £1175. Five years of aspirin, atenolol, and hydrochlorothiazide, is £718, including staff costs. The relative risk of cardiovascular disease with statin treatment is 0.7, with aspirin and antihypertensive drugs 0.6 (0.8×0.75=0.6). This will be explored further in a future paper.

We agree that there is an unresolved dilemma in cardiovascular prevention. A clinician acting in the best interests of an individual patient prescribes a statin; a clinician acting in the best interests of the whole practice population does not but employs a practice nurse to find and treat more patients. The former is consistent with the clinician’s duty of care but is a poor prevention policy. The latter is consistent with the optimum use of public funds.

We can also model the implications of Tyerman et al’s preference for prioritising 50 year olds over 70 year olds. For 50 and 70 year old men life expectancy is 25 years and 11 years, respectively, and cardiovascular disease at 57% of the cost.

Resource implications and health consequences of cardiovascular disease prevention with Tyerman et al’s suggestions

<table>
<thead>
<tr>
<th>No of patients assessed</th>
<th>No of patients eligible for any drug treatment</th>
<th>Workload (h)</th>
<th>Benefit: CVD events prevented per 5 years</th>
<th>Cost per 5 years (£)</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>75</td>
<td>Assessment clinic 50</td>
<td>9.2</td>
<td>222 967</td>
</tr>
<tr>
<td>200</td>
<td>113</td>
<td>Follow up clinic 75</td>
<td>10.3</td>
<td>269 687</td>
</tr>
<tr>
<td>300</td>
<td>135</td>
<td>90</td>
<td>10.8</td>
<td>301 994</td>
</tr>
<tr>
<td>400</td>
<td>147</td>
<td>98</td>
<td>11.2</td>
<td>388 099</td>
</tr>
<tr>
<td>893</td>
<td>163</td>
<td>108</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CVD=cardiovascular disease.
Critical of new German chronic disease management is unfair

Entworr—Tuffs’s news item on the new chronic disease management programmes in Germany is misleading.1

The new programmes have arisen from economic analysis showing the importance of ensuring that health insurance funds should not continue to be penalised financially when they have large numbers of patients with chronic diseases. The economic rationale for these programmes is not simply to fund deficits. These will be no extra money put into the system. Instead the existing risk adjustment strategy will take the higher costs for patients with chronic disease (initially type 2 diabetes and breast cancer) directly into account. Ultimately the government hopes to implement a new risk adjustment model that takes account of all pre-existing morbidity.

The federal government’s new programmes have arisen after the latest report of the Sachverständigenrat (the government’s advisory council) using data from the Organisation for Economic Co-operation and Development (OECD). Germany has the highest health expenditure in Europe with questionable quality of care. The programmes aim to eliminate overuse, underuse, and misuse of care.

The German Medical Society, statutory health insurance physicians, the hospitals society, and health insurance companies participated in the working group and the political committee that recommended these programmes to the government. The physicians could appoint their own experts and agree on all aspects of the programmes. All agreed, except for the hospitals society, which opposed requiring an evidence base for specific drugs. Thus it is hard to understand why the German Medical Society should have agreed on programmes that its president, Jörg-Dietrich Hoppe, now considers meet only minimal standards.2

Condemning the new disease management programmes as inferior to routine care is pure polemic. For the first time in German medicine, such programmes have been built on a solid basis of evidence based medicine, combining the best available evidence with clinical expertise.

We conclude that the doctors’ opposition to these programmes results from the deep cultural shock felt by those who thought that medical experts could never come into conflict with evidence based medicine, which for the first time has become an integral part of official governmental programmes. Physicians’ representatives are also not amused that the health insurance companies showed their willingness to become players rather than just payers in the development of these new disease management programmes.

These programmes will be updated regularly and must go through a tough process of certification and evaluation before they can become part of the risk adjustment mechanism. We strongly believe that they will enable us to overcome the important obstacles that we presently face in providing integrated care for people with chronic diseases.

Norbert Schmacke

Jörg Lauterberg

1 Tuffs A. Chronic disease management programmes are criticised by doctors. BMJ 2002;325:356. (17 August.)

Patient education is not a treatment modality

Entworr—In their editorial Riemmsma et al treat patient education in rheumatoid arthritis as a treatment modality, showing that it produces some minor improvements in a series of outcome measures.1

I have some reservations about treating patient education in this way. Providing people with medical conditions with information about their options is now an ethical requirement so that they can give informed consent. In such an uncertain and potentially life threatening and crippling condition as rheumatoid arthritis, health providers must supply as much information as patients require so that they can make the many decisions about their management in an informed way. It is an obligation, although knowledge can improve coping mechanisms and help internalise control, which both have beneficial long term effects.

It is also neither efficient nor effective a use of resources to prescribe all patients with a chronic disease such as rheumatoid arthritis counselling or behaviour modification. Armed with the facts from education sessions, many patients work out their own ways of coping and managing their condition, and this will not be improved by either counselling or behaviour modification. Some patients do need counselling to help them accept their condition and its implications and to plan for the future. Others with adverse health beliefs and dysfunctional behaviours will benefit from behaviour modification.

Thus I do not believe that judging these modalities by their effect on every member of a population with rheumatoid arthritis provides a true measure of their worth. Information giving is an ethical obligation. The indications for counselling and behaviour modification can be defined. It is in this group that the placebo clinical trials should be performed.

In this age of cost effectiveness, ethical obligations and modalities that are effective when targeted properly must not be cast away because they are not as effective as drug treatment in a population. They are designed for a different job. Every patient with rheumatoid arthritis would be given a hip replacement by this reckoning, for example.

Jeremy J Jones
consultant rheumatologist
Ysbyty Gwynedd, Bangor, Gwynedd LL57 2PW
jeremy.jones@mhw-tr.wales.nhs.uk